Congratulations, your contract development and manufacturing organization (CDMO) has just been awarded a new drug manufacturing contract! Your team competed hard for the opportunity, showcasing capabilities, hosting quality audits, and navigating sponsor due diligence. Internally, the work started long before the contract was signed. Leadership had to answer the critical questions every CDMO must ask: Does this fit our capabilities? Do we have the capacity? How robust is the process?

By the time the proposal went out the door, your cross-functional teams had modeled risks, pressure-tested assumptions, and weighed margin against operational exposure. Finally, the contract is signed and it’s a moment worth celebrating. But winning the deal is only the beginning! Now you face the moment of truth: tech transfer! This is the point where you must translate someone else’s science into your manufacturing reality.

Tech Transfer Is a Knowledge Transfer Problem

Too often, both CDMOs and sponsors treat tech transfers like a simple handoff of documents and procedures. But the reality is that it’s not just a paperwork exercise — it’s a knowledge transfer problem. And if that distinction isn’t fully appreciated from the start, the consequences can ripple throughout the entire program.

When things go wrong, the pain usually concentrates in three areas: incomplete process knowledge transfer, rocky analytical method transfer, and adapting development-scale processes to the realities of manufacturing equipment and scale. And when instability shows up during tech transfer, it doesn’t stay contained in that phase. It quickly translates into operational strain, commercial risk, and potential quality or regulatory consequences. In other words, tech transfer isn’t just a technical milestone — it’s a defining reputational moment.

How Sponsors Experience Tech Transfer

Tech transfer is the first real proof-of-performance moment with your sponsor. Up to this point, the sponsor has seen presentations, proposals, and audit responses. Now they see how you will execute.

If tech transfer goes well, it builds confidence quickly — trust starts to compound. If it doesn’t, the opposite happens just as fast. A rough transfer exposes knowledge gaps and raises uncomfortable questions for the sponsor who may wonder: If these disconnects are showing up now, what else are we missing?

Even when routine manufacturing later stabilizes, sponsors often remember the experience. A difficult tech transfer can cause them to view your CDMO as a schedule risk, which can jeopardize follow-on work such as moving from clinical to commercial manufacturing, expanding to new sites, or awarding additional products.

Digitalization: The Key to Smoother Tech Transfer

Successful tech transfer involves more than transferring process outputs and analytical methods. It requires transferring the knowledge needed to run them. Sponsors and CDMOs often think they’re transferring a complete package. But what’s missing is the “why” behind the processes, the edge cases, and tacit know-how accumulated during development. 

That knowledge must flow smoothly across the three critical interfaces where problems most often occur:

1. Knowledge transfer between R&D and MSAT
2. Process scale-up and operational readiness between MSAT and manufacturing
3. Method transfer between analytical development and QC.

Digitalization smooths the path for tech transfer by connecting critical process knowledge — process characterization data, risks, control strategies, and operating parameters, ensuring it is structured once and reused everywhere, instead of being rediscovered during every tech transfer attempt or validation cycle.

Without this visibility process knowledge tends to live in silos - in R&D teams, engineering groups, or a few subject matter experts. Tech transfer teams must then try to connect the dots across disparate information sources, operating downstream with incomplete or inconsistent context. The result is rework, late surprises, and failures that surface when timelines are already compressed.

Those operational issues can quickly translate into regulatory and quality pressure, often visible through rising deviations, CAPA investigations, and change controls and increasing audit friction as teams investigate, and correct problems that could have been prevented. With a centralized, accessible process knowledge base, many of these issues begin to fade away.

How AI Is Transforming Digitalized Tech Transfer

Digitalization and AI are beginning to change the dynamics of tech transfer by turning what has traditionally been a fragmented, document-heavy process into a structured, knowledge-driven one. 

AI systems can analyze historical process data, identify hidden relationships between parameters and outcomes, and help teams anticipate scale-up risks before they appear during engineering or PPQ runs. The result is a smoother translation of the science behind a drug into the realities of a manufacturing site. Teams can achieve more right-first-time execution, with fewer deviations, fewer delays, and lower regulatory risk.

In the end, tech transfer isn’t just about moving documents from one organization to another. It’s about transferring understanding. And as AI-powered digitalization matures, the CDMOs that master that knowledge transfer will be the ones that consistently deliver faster, safer, and more reliable tech transfers.